Volume | 1,479,992 |
|
|||||
News | - | ||||||
Day High | 16.80 | Low High |
|||||
Day Low | 15.915 |
Company Name | Stock Ticker Symbol | Market | Type |
---|---|---|---|
Denali Therapeutics Inc | DNLI | NASDAQ | Common Stock |
Open Price | Low Price | High Price | Close Price | Prev Close |
---|---|---|---|---|
16.50 | 15.915 | 16.80 | 16.00 | 16.60 |
Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
---|---|---|---|---|---|
16,621 | 1,479,992 | $ 16.22 | $ 24,000,302 | - | 15.45 - 33.31 |
Last Trade Time | Type | Quantity | Stock Price | Currency |
---|---|---|---|---|
18:31:52 | 1 | $ 16.10 | USD |
Denali Therapeutics Inc Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
2.23B | 139.16M | - | 330.53M | -145.22M | -1.04 | - |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
Denali Therapeutics News
Loading Messages....
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical DNLI Price Data
Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 18.97 | 19.01 | 15.915 | 17.33 | 1,129,928 | -2.97 | -15.66% |
1 Month | 20.98 | 21.04 | 15.915 | 18.89 | 987,141 | -4.98 | -23.74% |
3 Months | 17.39 | 23.52 | 15.49 | 19.04 | 1,216,752 | -1.39 | -7.99% |
6 Months | 19.30 | 23.81 | 15.45 | 19.24 | 1,116,164 | -3.30 | -17.10% |
1 Year | 25.69 | 33.31 | 15.45 | 21.97 | 909,313 | -9.69 | -37.72% |
3 Years | 54.17 | 79.70 | 15.45 | 31.31 | 719,378 | -38.17 | -70.46% |
5 Years | 24.83 | 93.94 | 12.39 | 33.10 | 640,449 | -8.83 | -35.56% |
Denali Therapeutics Description
Denali Therapeutics Inc is a biotechnology company that is engaged in developing and discovering therapeutics to defeat neurodegeneration disease. The company's development programs include the LRRK2 Inhibitor Program, which develops brain penetrant small molecule LRRK2 inhibitor product candidates for Parkinson's disease. Its key products include DNL201, DNL151, DNL747, ATV (Antibody Transport Vehicle), ETV (Enzyme Transport Vehicle), and others. |